Fig. 2: Anti-HBV activity of iCDM-34 and additive effects with entecavir (ETV) in primary cultured human hepatocytes. | Cell Death Discovery

Fig. 2: Anti-HBV activity of iCDM-34 and additive effects with entecavir (ETV) in primary cultured human hepatocytes.

From: A small molecule iCDM-34 identified by in silico screening suppresses HBV DNA through activation of aryl hydrocarbon receptor

Fig. 2

A The schematic experimental design of the anti-HBV activity analysis. Primary cultured human hepatocytes (PXB cells) were infected with HBV genotype C for 1 day (blue) and cultured for 14 days, and the cells were then treated with 3 and 30 μM iCDM-34 and CDM-3008 and 10 ng/mL pegylated interferon (pegIFN)-α2a for 7 days (orange). The black arrows show the time points of medium changes. After the treatments, cell viability was measured and cellular DNA was purified. B Cell viability was measured by RealTime-Glo MT Cell Viability Assay and shown as % of DMSO control. C Cellular HBV DNA levels in 1 ng DNA were measured. D Medium HBV DNA levels were measured in the medium. E, F HBsAg and HBeAg levels in the medium were measured by ELISA. Error bars indicate SD (n = 3). *p < 0.05 and **p < 0.01 (two-tailed t test).

Back to article page